Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HOLOGIC INCHOLX · Entity 12463 | Group Pres, Global Diagnostics | November 15, 2022 | November 17, 2022 |
| ZIMMER BIOMET HOLDINGS, INC.ZBH · Entity 3278 | Grp Pres-Global Business | September 11, 2026 | September 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HOLOGIC INC
Report date November 15, 2022 · Filed November 17, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 62,368 |
Ending reported balance
After 2022-11-15 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2022-11-15 · Sale · Disposed 6,628 · Balance 62,368 F1: The price reported is the weighted average price per share. Shares were sold in multiple transactions at prices ranging from $75.35 to $75.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price. Row 2 · 2022-11-15 · Exercise / conversion · Acquired 12,490 · Balance 74,858 Row 3 · 2022-11-15 · Sale · Disposed 12,490 · Balance 62,368 F2: The price reported is the weighted average price per share. Shares were sold in multiple transactions at prices ranging from $75.26 to $75.372 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.85 · Expires 2027-12-01 | Direct | 0 |
Reported balance
After 2022-11-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-11-15 · Exercise / conversion · Disposed 12,490 · Balance 0 F3: This option to purchase common stock becomes exercisable in equal installments on each of the first four anniversaries of the grant date, December 1, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is the weighted average price per share. Shares were sold in multiple transactions at prices ranging from $75.35 to $75.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price.
F2: The price reported is the weighted average price per share. Shares were sold in multiple transactions at prices ranging from $75.26 to $75.372 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price.
F3: This option to purchase common stock becomes exercisable in equal installments on each of the first four anniversaries of the grant date, December 1, 2017.
ZIMMER BIOMET HOLDINGS, INC.
Report date September 11, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 1
1 source rowRow 1 · 2026-09-11 · Sale · Disposed 5,691 · Balance 0 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NEVRO CORP
Report date April 03, 2025 · Filed April 03, 2025
Section 16 reporting ended · disclosed 2025-04-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-04-03 transaction · row 1
1 source rowRow 1 · 2025-04-03 · Disposition to issuer · Disposed 852,337 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time"). F2: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time").
F2: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2026 Filed Sep 15, 2026 20:24 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | SaleCommon Stock | 5,691 | $92.95 | $528,978.45 |
DisclosureSEC source: 0001783992-26-000006 · form4-09152026_080921.xml · nonDerivative · entry 1 Thornal Kevin R · CIK 0001783992 · Grp Pres-Global Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| August 01, 2026 Filed Aug 4, 2026 20:18 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Exercise / conversionRestricted Stock Units · Derivative | 9,957 | $0.00 | $0.00 |
DisclosureSEC source: 0001783992-26-000004 · form4-08042026_080809.xml · derivative · entry 3 Thornal Kevin R · CIK 0001783992 · Grp Pres-Global Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,913 Underlying: Common Stock · 9,957 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Company common stock. F3 · derivative.exercise_date: One-third of the RSUs vested on August 1, 2026. The remaining RSUs vest one-half on each of August 1, 2027 and August 1, 2028. F3 · derivative.expiration_date: One-third of the RSUs vested on August 1, 2026. The remaining RSUs vest one-half on each of August 1, 2027 and August 1, 2028. Read SEC document |
| August 01, 2026 Filed Aug 4, 2026 20:18 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Tax withholdingCommon Stock | 4,266 | $92.68 | $395,372.88 |
DisclosureSEC source: 0001783992-26-000004 · form4-08042026_080809.xml · nonDerivative · entry 2 Thornal Kevin R · CIK 0001783992 · Grp Pres-Global Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,691 F1 · shares: Represents shares withheld by Zimmer Biomet Holdings, Inc. (the "Company") to satisfy tax withholding obligations on the vesting of restricted stock units ("RSUs"). Read SEC document |
| August 01, 2026 Filed Aug 4, 2026 20:18 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Exercise / conversionCommon Stock | 9,957 | $0.00 | $0.00 |
DisclosureSEC source: 0001783992-26-000004 · form4-08042026_080809.xml · nonDerivative · entry 1 Thornal Kevin R · CIK 0001783992 · Grp Pres-Global Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2026 Filed Feb 25, 2026 02:02 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantRestricted Stock Units · Derivative | 27,385 | $0.00 | $0.00 |
DisclosureSEC source: 0001783992-26-000002 · form4-02252026_020242.xml · derivative · entry 1 Thornal Kevin R · CIK 0001783992 · Grp Pres-Global Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,385 Underlying: Common Stock · 27,385 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Company common stock. F2 · derivative.exercise_date: Vests annually over three years in increments of one-third each year, commencing February 20, 2027. F2 · derivative.expiration_date: Vests annually over three years in increments of one-third each year, commencing February 20, 2027. Read SEC document |
| August 01, 2025 Filed Aug 13, 2025 20:15 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantRestricted Stock Units · Derivative | 29,870 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014300 · form4.xml · derivative · entry 1 Thornal Kevin R · CIK 0001783992 · Grp Pres-Global Bus. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,870 Underlying: Common Stock · 29,870 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock. F2 · derivative.exercise_date: One-third of the RSUs shall vest on each of August 1, 2026, August 1, 2027 and August 1, 2028. F2 · derivative.expiration_date: One-third of the RSUs shall vest on each of August 1, 2026, August 1, 2027 and August 1, 2028. Read SEC document |
| April 03, 2025 Filed Apr 3, 2025 16:30 UTC | NEVRO CORP NVRO · Entity 12422 | Disposition to issuerCommon Stock | 852,337 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-050465 · ownership.xml · nonDerivative · entry 1 Thornal Kevin R · CIK 0001783992 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time"). F2 · price: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 17:23 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 27,029 | $5.77 | $155,957.33 |
DisclosureSEC source: 0001444380-25-000041 · wk-form4_1741728217.xml · nonDerivative · entry 1 Thornal Kevin R · CIK 0001783992 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,133 F1 · balance_after: Includes 156,897 restricted stock units. Read SEC document |
| January 24, 2025 Filed Jan 27, 2025 16:17 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 6,685 | $5.16 | $34,494.60 |
DisclosureSEC source: 0001444380-25-000014 · wk-form4_1738012618.xml · nonDerivative · entry 1 Thornal Kevin R · CIK 0001783992 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,162 F1 · balance_after: Includes 207,091 restricted stock units. Read SEC document |
| October 24, 2024 Filed Oct 28, 2024 16:06 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 6,063 | $4.85 | $29,405.55 |
DisclosureSEC source: 0001610717-24-000515 · form4.xml · nonDerivative · entry 1 Thornal Kevin R · CIK 0001783992 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 249,847 F1 · balance_after: Includes 218,393 restricted stock units. Read SEC document |
| July 24, 2024 Filed Jul 26, 2024 16:43 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 6,061 | $9.74 | $59,034.14 |
DisclosureSEC source: 0001610717-24-000409 · form4.xml · nonDerivative · entry 1 Thornal Kevin R · CIK 0001783992 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 255,910 F1 · balance_after: Includes 229,695 restricted stock units. Read SEC document |
| April 24, 2024 Filed Apr 26, 2024 17:00 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 24,233 | $12.51 | $303,154.83 |
DisclosureSEC source: 0001610717-24-000226 · form4.xml · nonDerivative · entry 1 Thornal Kevin R · CIK 0001783992 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 261,971 F1 · balance_after: Includes 240,996 restricted stock units. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 16:53 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 150,581 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000148 · form4.xml · nonDerivative · entry 1 Thornal Kevin R · CIK 0001783992 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 286,204 F1 · shares: Constitutes restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. 1/3rd of the RSUs will vest on March 7, 2025 and the remainder will vest quarterly thereafter, such that all RSUs will be fully vested by the third anniversary of the grant date, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 286,204 RSUs. Read SEC document |
| April 24, 2023 Filed Apr 26, 2023 17:55 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 135,623 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000031 · form4.xml · nonDerivative · entry 1 Thornal Kevin R · CIK 0001783992 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,623 F1 · shares: Constitutes restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. 1/3rd of the RSUs will vest on April 24, 2024 (the "Anniversary Date"), and 1/12th of the RSUs will vest in equal quarterly installments thereafter following the Anniversary Date, such that all RSUs will have vested on the third anniversary of the grant date, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 135,623 RSUs. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 21:29 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 12,490 | $0.00 Strike: $40.85 | $0.00 |
DisclosureSEC source: 0001127602-22-025948 · form4.xml · derivative · entry 4 Thornal Kevin R · CIK 0001783992 · Group Pres, Global Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,490 shares Expires 2027-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option to purchase common stock becomes exercisable in equal installments on each of the first four anniversaries of the grant date, December 1, 2017. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 21:29 UTC | HOLOGIC INC HOLX · Entity 12463 | SaleCommon Stock | 12,490 | $75.30 | $940,509.49 |
DisclosureSEC source: 0001127602-22-025948 · form4.xml · nonDerivative · entry 3 Thornal Kevin R · CIK 0001783992 · Group Pres, Global Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,368 F2 · price: The price reported is the weighted average price per share. Shares were sold in multiple transactions at prices ranging from $75.26 to $75.372 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 21:29 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionCommon Stock | 12,490 | $40.85 | $510,216.50 |
DisclosureSEC source: 0001127602-22-025948 · form4.xml · nonDerivative · entry 2 Thornal Kevin R · CIK 0001783992 · Group Pres, Global Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,858 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 21:29 UTC | HOLOGIC INC HOLX · Entity 12463 | SaleCommon Stock | 6,628 | $75.37 | $499,552.36 |
DisclosureSEC source: 0001127602-22-025948 · form4.xml · nonDerivative · entry 1 Thornal Kevin R · CIK 0001783992 · Group Pres, Global Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,368 F1 · price: The price reported is the weighted average price per share. Shares were sold in multiple transactions at prices ranging from $75.35 to $75.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| November 11, 2022 Filed Nov 14, 2022 21:43 UTC | HOLOGIC INC HOLX · Entity 12463 | Tax withholdingCommon Stock | 8,780 | $75.93 | $666,665.40 |
DisclosureSEC source: 0001127602-22-025497 · form4.xml · nonDerivative · entry 2 Thornal Kevin R · CIK 0001783992 · Group Pres, Global Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,996 F1 · shares: Shares withheld for tax obligations in connection with the settlement of restricted stock units/performance stock units for which service-based vesting requirements have been satisfied. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 21:43 UTC | HOLOGIC INC HOLX · Entity 12463 | Tax withholdingCommon Stock | 591 | $72.11 | $42,617.01 |
DisclosureSEC source: 0001127602-22-025497 · form4.xml · nonDerivative · entry 1 Thornal Kevin R · CIK 0001783992 · Group Pres, Global Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,776 F1 · shares: Shares withheld for tax obligations in connection with the settlement of restricted stock units/performance stock units for which service-based vesting requirements have been satisfied. Read SEC document |
| November 08, 2022 Filed Nov 9, 2022 22:13 UTC | HOLOGIC INC HOLX · Entity 12463 | Tax withholdingCommon Stock | 709 | $73.71 | $52,260.39 |
DisclosureSEC source: 0001127602-22-025217 · form4.xml · nonDerivative · entry 2 Thornal Kevin R · CIK 0001783992 · Group Pres, Global Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,367 Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 22:13 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 19,327 | $0.00 Strike: $74.35 | $0.00 |
DisclosureSEC source: 0001127602-22-025217 · form4.xml · derivative · entry 3 Thornal Kevin R · CIK 0001783992 · Group Pres, Global Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,327 Underlying: Common Stock · 19,327 shares Expires 2032-11-07 F3 · derivative.exercise_date: This option to purchase common stock becomes exercisable in equal installments on each of the first four anniversaries of the grant date, November 7, 2022. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 22:13 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 6,724 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-025217 · form4.xml · nonDerivative · entry 1 Thornal Kevin R · CIK 0001783992 · Group Pres, Global Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,076 F1 · shares: Represents restricted stock units which vest in equal installments on each of the first three anniversaries of the grant date, November 7, 2022. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:46 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 12,277 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-024911 · form4.xml · nonDerivative · entry 1 Thornal Kevin R · CIK 0001783992 · Div. President, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,352 F1 · shares: Represents performance stock units as to which the performance criteria has been satisfied but which remain subject to service-based vesting requirements. F2 · price: Performance stock units are settled in shares of common stock on a one-for-one basis. Read SEC document |
| November 12, 2021 Filed Nov 15, 2021 21:21 UTC | HOLOGIC INC HOLX · Entity 12463 | Tax withholdingCommon Stock | 6,833 | $73.54 | $502,498.82 |
DisclosureSEC source: 0001127602-21-029115 · form4.xml · nonDerivative · entry 2 Thornal Kevin R · CIK 0001783992 · Div. President, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,075 Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 21:21 UTC | HOLOGIC INC HOLX · Entity 12463 | Tax withholdingCommon Stock | 632 | $72.61 | $45,889.52 |
DisclosureSEC source: 0001127602-21-029115 · form4.xml · nonDerivative · entry 1 Thornal Kevin R · CIK 0001783992 · Div. President, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,908 Read SEC document |
| November 09, 2021 Filed Nov 10, 2021 21:33 UTC | HOLOGIC INC HOLX · Entity 12463 | Tax withholdingCommon Stock | 590 | $71.26 | $42,043.40 |
DisclosureSEC source: 0001127602-21-028820 · form4.xml · nonDerivative · entry 2 Thornal Kevin R · CIK 0001783992 · Div. President, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,540 Read SEC document |
| November 08, 2021 Filed Nov 10, 2021 21:33 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 20,803 | $0.00 Strike: $71.13 | $0.00 |
DisclosureSEC source: 0001127602-21-028820 · form4.xml · derivative · entry 3 Thornal Kevin R · CIK 0001783992 · Div. President, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,803 Underlying: Common Stock · 20,803 shares Expires 2031-11-08 F3 · derivative.exercise_date: This option to purchase common stock becomes exercisable in equal installments on each of the first four anniversaries of the grant date, November 8, 2021. Read SEC document |
| November 08, 2021 Filed Nov 10, 2021 21:33 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 6,150 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-028820 · form4.xml · nonDerivative · entry 1 Thornal Kevin R · CIK 0001783992 · Div. President, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,130 F1 · shares: Represents restricted stock units which vest in equal installments on each of the first three anniversaries of the grant date, November 8, 2021. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:25 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 28,764 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-028279 · form4.xml · nonDerivative · entry 1 Thornal Kevin R · CIK 0001783992 · Div. President, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,980 F1 · shares: Represents performance stock units as to which the performance criteria has been satisfied but which remain subject to service-based vesting requirements. F2 · price: Performance stock units are settled in shares of common stock on a one-for-one basis. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 21:44 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 9,236 | $0.00 Strike: $37.64 | $0.00 |
DisclosureSEC source: 0001127602-20-031285 · form4.xml · derivative · entry 6 Thornal Kevin R · CIK 0001783992 · Div. President, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,236 shares Expires 2026-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option to purchase common stock became exercisable in equal installments on each of the first four anniversaries of the grant date, December 1, 2016. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 21:44 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 7,633 | $0.00 Strike: $39.96 | $0.00 |
DisclosureSEC source: 0001127602-20-031285 · form4.xml · derivative · entry 5 Thornal Kevin R · CIK 0001783992 · Div. President, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,633 shares Expires 2025-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option to purchase common stock became exercisable in equal installments on each of the first four anniversaries of the grant date, November 5, 2015. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 21:44 UTC | HOLOGIC INC HOLX · Entity 12463 | SaleCommon Stock | 9,236 | $73.99 | $683,408.58 |
DisclosureSEC source: 0001127602-20-031285 · form4.xml · nonDerivative · entry 4 Thornal Kevin R · CIK 0001783992 · Div. President, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,216 F1 · price: The price reported is the weighted average price per share. Shares were sold in multiple transactions at prices ranging from $73.98 to $74.01 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 21:44 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionCommon Stock | 9,236 | $37.64 | $347,643.04 |
DisclosureSEC source: 0001127602-20-031285 · form4.xml · nonDerivative · entry 3 Thornal Kevin R · CIK 0001783992 · Div. President, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 21:44 UTC | HOLOGIC INC HOLX · Entity 12463 | SaleCommon Stock | 7,633 | $74.00 | $564,803.84 |
DisclosureSEC source: 0001127602-20-031285 · form4.xml · nonDerivative · entry 2 Thornal Kevin R · CIK 0001783992 · Div. President, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,216 Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 21:44 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionCommon Stock | 7,633 | $39.96 | $305,014.68 |
DisclosureSEC source: 0001127602-20-031285 · form4.xml · nonDerivative · entry 1 Thornal Kevin R · CIK 0001783992 · Div. President, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 22:07 UTC | HOLOGIC INC HOLX · Entity 12463 | Tax withholdingCommon Stock | 5,450 | $69.63 | $379,483.50 |
DisclosureSEC source: 0001127602-20-030463 · form4.xml · nonDerivative · entry 1 Thornal Kevin R · CIK 0001783992 · Div. President, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,216 Read SEC document |
| November 12, 2020 Filed Nov 16, 2020 21:34 UTC | HOLOGIC INC HOLX · Entity 12463 | Tax withholdingCommon Stock | 598 | $70.20 | $41,979.60 |
DisclosureSEC source: 0001127602-20-029139 · form4.xml · nonDerivative · entry 1 Thornal Kevin R · CIK 0001783992 · Div. President, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,666 Read SEC document |
| November 11, 2020 Filed Nov 12, 2020 22:41 UTC | HOLOGIC INC HOLX · Entity 12463 | Tax withholdingCommon Stock | 632 | $69.84 | $44,138.88 |
DisclosureSEC source: 0001127602-20-028859 · form4.xml · nonDerivative · entry 2 Thornal Kevin R · CIK 0001783992 · Div. President, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,264 Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 22:41 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 17,512 | $0.00 Strike: $68.35 | $0.00 |
DisclosureSEC source: 0001127602-20-028859 · form4.xml · derivative · entry 3 Thornal Kevin R · CIK 0001783992 · Div. President, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,512 Underlying: Common Stock · 17,512 shares Expires 2030-11-09 F3 · derivative.exercise_date: This option to purchase common stock becomes exercisable in equal installments on each of the first four anniversaries of the grant date, November 9, 2020. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 22:41 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 5,120 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-028859 · form4.xml · nonDerivative · entry 1 Thornal Kevin R · CIK 0001783992 · Div. President, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,896 F1 · shares: Represents restricted stock units which vest in equal installments on each of the first three anniversaries of the grant date, November 9, 2020. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:37 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 17,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-028178 · form4.xml · nonDerivative · entry 1 Thornal Kevin R · CIK 0001783992 · Div. President, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,776 F1 · shares: Represents performance stock units as to which the performance criteria has been satisfied but which remain subject to service-based vesting requirements. F2 · price: Performance stock units are settled in shares of common stock on a one-for-one basis. Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:09 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 13,888 | $0.00 Strike: $26.01 | $0.00 |
DisclosureSEC source: 0001127602-20-017145 · form4.xml · derivative · entry 3 Thornal Kevin R · CIK 0001783992 · Div. President, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,888 shares Expires 2021-08-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option to purchase common stock became exercisable in equal installments on each of the first five anniversaries of the grant date, August 13, 2014. Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:09 UTC | HOLOGIC INC HOLX · Entity 12463 | SaleCommon Stock | 13,888 | $51.51 | $715,426.43 |
DisclosureSEC source: 0001127602-20-017145 · form4.xml · nonDerivative · entry 2 Thornal Kevin R · CIK 0001783992 · Div. President, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,026 F1 · price: The price reported is the weighted average price per share. Shares were sold in multiple transactions at prices ranging from $51.28 to $51.64 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:09 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionCommon Stock | 13,888 | $26.01 | $361,226.88 |
DisclosureSEC source: 0001127602-20-017145 · form4.xml · nonDerivative · entry 1 Thornal Kevin R · CIK 0001783992 · Div. President, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 21:12 UTC | HOLOGIC INC HOLX · Entity 12463 | Tax withholdingCommon Stock | 658 | $51.32 | $33,768.56 |
DisclosureSEC source: 0001127602-19-034117 · form4.xml · nonDerivative · entry 2 Thornal Kevin R · CIK 0001783992 · Div. President, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,026 Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 21:12 UTC | HOLOGIC INC HOLX · Entity 12463 | Tax withholdingCommon Stock | 494 | $51.32 | $25,352.08 |
DisclosureSEC source: 0001127602-19-034117 · form4.xml · nonDerivative · entry 1 Thornal Kevin R · CIK 0001783992 · Div. President, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,684 Read SEC document |
| November 12, 2019 Filed Nov 13, 2019 22:21 UTC | HOLOGIC INC HOLX · Entity 12463 | Tax withholdingCommon Stock | 857 | $46.15 | $39,550.55 |
DisclosureSEC source: 0001127602-19-032641 · form4.xml · nonDerivative · entry 2 Thornal Kevin R · CIK 0001783992 · Div. President, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,178 Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 22:21 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 18,102 | $0.00 Strike: $45.61 | $0.00 |
DisclosureSEC source: 0001127602-19-032641 · form4.xml · derivative · entry 3 Thornal Kevin R · CIK 0001783992 · Div. President, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,102 Underlying: Common Stock · 18,102 shares Expires 2029-11-11 F3 · derivative.exercise_date: This option to purchase common stock becomes exercisable in equal installments on each of the first four anniversaries of the grant date, November 11, 2019. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 22:21 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 5,481 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-032641 · form4.xml · nonDerivative · entry 1 Thornal Kevin R · CIK 0001783992 · Div. President, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,035 F1 · shares: Represents restricted stock units which vest in equal installments on each of the first three anniversaries of the grant date, November 11, 2019. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.